| Literature DB >> 19443091 |
Volia De Carvalho Almeida1, Marisa Márcia Mussi-Pinhata, Cleonice Barbosa Sandoval De Souza, Christina Arslanian Kubo, Edson Zangiacomi Martinez, Magda Maria Carneiro-Sampaio, Geraldo Duarte.
Abstract
Whether gestational immunization of HIV-infected mothers with the 23-valent pneumococcal polysaccharide vaccine (PPV) confers maternal and infant early life, passive protection is not known. We evaluated safety, immunogenicity and placental transfer of antibodies in 44 HIV-infected women. Pneumococcal IgG antibodies against serotypes 1, 3, 5, 6B, 9V, and 14 were measured in mothers (pre-vaccination and at delivery), and infants (at birth, 1, 2, 3, and 6 months). PPV was safe and immunogenic in mothers. Newborns received 46-72% of maternal antibody titers. Overall, infants had antibody levels lower than protective by 2 months of age. Alternative pneumococcal vaccination of HIV-infected pregnant women should be explored with the aim of prolonging passive protection in their infants.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19443091 DOI： 10.1016/j.vaccine.2009.04.018
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641